Search results
Abbvie Inc (ABBV) Shares Up Despite Recent Market Volatility – News Heater
NewsHeater· 4 days agoThe stock price of Abbvie Inc (NYSE: ABBV) has surged by 1.06 when compared to previous closing price of 164.66, but the company has seen a 2.54% gain in ...
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study By...
Investing.com· 16 hours agoAbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
Cigna to offer Humira rivals with $0 copay at specialty pharmacy
Reuters· 14 hours agoCigna plans to make close copies of AbbVie's blockbuster arthritis drug Humira available with no...
AbbVie Q1 Preview: Skyrizi and Rinvoq’s launches could help Q1 (NYSE:ABBV)
Seeking Alpha· 20 hours agoAbbVie (ABBV) is set to report Q1 earnings results on April 26th. Analysts expect a profit of $2.26...
AbbVie Inc. (NYSE:ABBV) to Post Q1 2024 Earnings of $2.21 Per Share, William Blair Forecasts
ETF DAILY NEWS· 6 days agoAbbVie Inc. (NYSE:ABBV – Free Report) – Research analysts at William Blair issued their Q1 2024 EPS estimates for AbbVie in a research note issued to investors ...
FY2025 EPS Estimates for AbbVie Inc. (NYSE:ABBV) Lowered by Analyst
ETF DAILY NEWS· 6 days agoAbbVie Inc. (NYSE:ABBV – Free Report) – Investment analysts at William Blair dropped their FY2025 EPS estimates for shares of AbbVie in a report released ...
AbbVie (NYSE:ABBV) Shares Up 1.8%
ETF DAILY NEWS· 6 days agoAbbVie Inc. (NYSE:ABBV – Get Free Report) shot up 1.8% on Thursday . The company traded as high as $167.44 and last traded at $167.14. BMO Capital Markets ...
AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study
Reuters· 19 hours agoAbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory skin condition was found to be more effective than Regeneron Pharmaceuticals and Sanofi's Dupixent in a late-stage head-to-head study.
AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 4 days agoThe company has a trailing four-quarter earnings surprise of 2.34%, on average. AbbVie Inc. Price...
What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
Zacks via Yahoo Finance· 2 days agoAbbVie’s top line is expected to have been driven by sales of new immunology drugs, Skyrizi and...